Cancers, Vol. 11, Pages 577: Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts

Cancers, Vol. 11, Pages 577: Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts Cancers doi: 10.3390/cancers11040577 Authors: Holly A. Maulhardt Lauren Hylle Michael V. Frost Ashley Tornio Sara Dafoe Leanne Drummond David I. Quinn Ashish M. Kamat Gere S. diZerega Intratumoral (IT) administration of submicron particle docetaxel (NanoDoce®, NanOlogy LLC, Fort Worth, TX, USA) and its efficacy against genitourinary-oncologic xenografts in rats and mice, xenograft-site docetaxel concentrations and immune-cell infiltration were studied. IT-NanoDoce®, IV-docetaxel and IT-vehicle were administered to clear cell renal carcinoma (786-O: rats), transitional cell bladder carcinoma (UM-UC-3: mice) and prostate carcinoma (PC-3: mice). Treatments were given every 7 days with 1, 2, or 3 doses administered. Animals were followed for tumor growth and clinical signs. At necropsy, 786-O and UM-UC-3 tumor-site tissues were evaluated by H&E and IHC and analyzed by LC-MS/MS for docetaxel concentration. Two and 3 cycles of IT-NanoDoce® significantly reduced UM-UC-3 tumor volume (p < 0.01) and eliminated most UM-UC-3 and 786-O tumors. In both models, NanoDoce® treatment was associated with (peri)tumor-infiltrating immune cells. Lymphoid structures were observed in IT-NanoDoce®-treated UM-UC-3 animals adjacen...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research

Related Links:

ConclusionsThe addition of the botanical formula LCS101 to irradiated cancer cells results in an apparent additive effect, most likely through a ROS-mediated mechanism. These findings support the use of LCS101 by patients undergoing radiation therapy, for both its clinical as well as anti-cancer effects.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
We report a patient that had a prior radical prostatectomy and negative PSA levels for two years and subsequently developed bladder cancer requiring radical cystectomy with mixed lymph nodes on final pathology. The nodes were found to be positive for both metastatic urothelial cell carcinoma and metastatic prostatic adenocarcinoma based on immunohistochemical staining. Treatment for metastatic bladder cancer was pursued after radical cystectomy recovery.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: July 2018Source: European Urology, Volume 74, Issue 1Author(s): Wei Shen Tan, Andrew Feber, Rachael Sarpong, Pramit Khetrapal, Simon Rodney, Rumana Jalil, Hugh Mostafid, Joanne Cresswell, James Hicks, Abhay Rane, Alastair Henderson, Dawn Watson, Jacob Cherian, Norman Williams, Chris Brew-Graves, John D. Kelly, on behalf of DETECT I trial collaboratorsAbstractThere remains a lack of consensus among guideline relating to which patients require investigation for haematuria. We determined the incidence of urinary tract cancer in a prospective observational study of 3556 patients referred for investigation of ...
Source: European Urology - Category: Urology & Nephrology Source Type: research
We report a patient that had a prior radical prostatectomy and negative PSA levels for two years and subsequently developed bladder cancer requiring radical cystectomy with mixed lymph nodes on final pathology. The nodes were found to be positive for both metastatic urothelial cell carcinoma and metastatic prostatic adenocarcinoma based on immunohistochemical staining. Treatment for metastatic bladder cancer was pursued after radical cystectomy recovery.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: July 2018Source: European Urology, Volume 74, Issue 1Author(s): Wei Shen Tan, Andrew Feber, Rachael Sarpong, Pramit Khetrapal, Simon Rodney, Rumana Jalil, Hugh Mostafid, Joanne Cresswell, James Hicks, Abhay Rane, Alastair Henderson, Dawn Watson, Jacob Cherian, Norman Williams, Chris Brew-Graves, John D. Kelly, on behalf of DETECT I trial collaboratorsAbstractThere remains a lack of consensus among guideline relating to which patients require investigation for haematuria. We determined the incidence of urinary tract cancer in a prospective observational study of 3556 patients referred for investigation of ...
Source: European Urology - Category: Urology & Nephrology Source Type: research
In this study, we investigated the clinical value of diuretic delayed 18F-FDG PET/CT via taking small dose of diuretics orally in diagnosing urogential cancers. To our knowledge, it is the first report which has successfully used the oral intake of small dose of furosemide in diuretic 18F-FDG PET/CT. Methods: Forty-seven patients suspected of urogenital cancers from 2015 to 2017 were divided into small dosage group (26 males and 9 females, aged 33-82 years, 20mg furosemide) and routine dosage group (9 males and 3 females, aged 50-80 years, 40mg furosemide). All patients underwent whole body PET/CT scan (Discovery, GE Healt...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Posters Source Type: research
We report a patient that had a prior radical prostatectomy and negative PSA levels for two years and subsequently developed bladder cancer requiring radical cystectomy with mixed lymph nodes on final pathology. The nodes were found to be positive for both metastatic urothelial cell carcinoma and metastatic prostatic adenocarcinoma based on immunohistochemical staining. Treatment for metastatic bladder cancer was pursued after radical cystectomy recovery.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
This study highlights the requirement to investigate all patients with visible blood in the urine and an age threshold of ≥60 yr, as recommended in some guidelines, as the investigation of nonvisible blood in the urine will miss a significant number of urinary tract cancers. Patient preference is important, and evidence that patients are willing to submit to investigation should be considered in reaching a consensus recommendation for the investigation of haematuria. International consensus to guide that patients will benefit from investigation should be developed. Visible haematuria should be investigated regardless of...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Authors: Ştefănescu ML, Grosu F, Stoica LE, Schenker M, Mogoantă L, Bastian AE Abstract Worldwide, bladder cancer is the seventh most frequent cancer in men and the 17th most frequent cancer in women, respectively. In men, this type of cancer is the second most frequent type of cancer localized in the genitourinary system, after prostate cancer. The incidence of bladder cancer is ever growing and the etiopathogenic factors of bladder cancer are numerous and still not fully understood. Smoking is the most common risk factor incriminated in the onset of urinary tract cancer, the incidence of bladder cancer being d...
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research
ABSTRACT Introduction Carcinosarcoma of the bladder is a very rare neoplasm. The pathogenesis of carcinosarcomas is not clearly understood and remains a subject of debate. Whilst there is some research conceptualizing the histopathological findings of bladder carcinosarcomas, the demographic features, clinical outcomes, prognosis and treatment options remain unclear. Materials and Methods We analyzed 12 consecutive cases of patients with sarcoma-toid bladder cancer who were treated surgically at a single Urology Department be-tween 1999 and 2015. Radiology, pathology and surgical reports were reviewed to determine the path...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
More News: Allergy & Immunology | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Docetaxel | Nanotechnology | Prostate Cancer | Study | Taxotere | Toxicology | Transitional Cell Carcinoma